Indaptus Therapeutics (INDP) Stock Forecast: StockMap's 2-Week Call

INDP stock forecast: StockMap's model makes no two-week call on Indaptus Therapeutics after the Nov 19 close: its evidence is split, 4 reasons for and 9 against. Right in 3 of 6 two-week windows on INDP since Aug 21; by chance, a call on the same dates was right 59% of the time.

Indaptus Therapeutics last closed at $3.13, -4.86% on the session.

Against the IVW growth benchmark the position is -2.53% over the forecast window.

Indaptus Therapeutics' market cap is $480.79M as of November 19, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 6 (too close to call).

Where INDP sits: sized by market cap, coloured by the day's move.

The read is built from 13 underlying insights — 4 bullish and 9 bearish.

Agreement across those insights is 31%.

41 daily calls for INDP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Indaptus Therapeutics in the 3rd percentile on return on equity, where 100 is best.

Indaptus Therapeutics is classified under Health Care / Biotechnology.

StockMap tracks Indaptus Therapeutics as the 174th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Indaptus Therapeutics ranks 44th of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Indaptus Therapeutics (INDP) — StockMap 2-week forecast & tracked accuracy